Compounds / GLOW Blend
GLOW Blend
Also known as: GLOW Stack; GHK-Cu + BPC-157 + TB-500 blend; GLOW 70mg (50/10/10); three-peptide repair and skin blend
Primary research focus: Tissue-repair and skin-remodeling research (combined GHK-Cu, BPC-157, and TB-500 blend)
Last updated July 2026 · Reviewed against FDA labeling and published research.
What is GLOW Blend?
The GLOW Blend combines GHK-Cu, BPC-157, and TB-500 in a single co-lyophilized vial. It is the Wolverine repair backbone (BPC-157 plus TB-500) with GHK-Cu added for collagen and skin remodeling. The standard presentation is a 70 mg vial split 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500; smaller vials (for example 10 mg total, split 5 mg / 2.5 mg / 2.5 mg) also exist at the same ratio. It is a vendor and community construct, not a studied compound, and it raises copper-related stability concerns that the simpler Wolverine blend does not.
The blend has no mechanism of its own; it is three separate proposed mechanisms in one vial. GHK-Cu binds copper(II) and delivers it to cells while modulating a very broad gene-expression program affecting extracellular-matrix remodeling, collagen and elastin synthesis, and angiogenesis. BPC-157 is studied for local angiogenesis via VEGFR2-Akt-eNOS signaling and growth-factor modulation, with no identified receptor. TB-500 (Ac-LKKTETQ) binds G-actin and regulates actin polymerization, driving cell migration and angiogenesis. The stated rationale is complementary coverage: copper-mediated matrix activation, cytoprotective signaling, and actin-dependent cell motility. Note the ratio is heavily skewed toward GHK-Cu (roughly 71 percent of vial mass) not because it is the most important component but because effective GHK-Cu amounts are in the milligram range while BPC-157 and TB-500 are typically used at microgram-level doses. Synergy across the three has not been demonstrated in any published trial.
How it’s supplied
Not an FDA-approved or commercially manufactured medicine. It is sold by research-chemical vendors as a single co-lyophilized, filler-free vial, most commonly 70 mg total (50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500). Smaller vials at the same 5:1:1 ratio (for example 10 mg total: 5 mg / 2.5 mg / 2.5 mg) are also sold. Some vendors cite roughly 72 hours of post-reconstitution stability at 4 degrees C, though the basis for that figure is not independently established. It is also available as three separate vials, which is the safer path.
Dosage Chart
Units shown are for a U-100 insulin syringe (100 units = 1 mL), calculated from the vial size and BAC water you select. For a blend, set the vial size to the total of all peptides in the vial; each dose is the combined amount, so one unit figure draws every component together in its fixed ratio. Always confirm against your prescription and your syringe markings.
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Weeks 1-2 | GHK-Cu: 1mgBPC-157: 200mcgTB-500: 200mcg | 1x Daily | — |
| Weeks 3-4 | GHK-Cu: 2mgBPC-157: 400mcgTB-500: 400mcg | 1x Daily | — |
| Weeks 5-8 | GHK-Cu: 3mgBPC-157: 600mcgTB-500: 600mcg | 1x Daily | — |
- Rotate injection sites to reduce irritation and lipohypertrophy
- Not for use during pregnancy or breastfeeding
- Do not exceed the recommended dose to try to speed results
Potential Benefits and Side Effects
Effects reported in published research. Not a promise of results, and not medical advice.
- Reported for the individual components in preclinical research and, for GHK-Cu, small human topical studies; no benefit has been demonstrated for the blend.
- GHK-Cu: stimulation of collagen, elastin, and glycosaminoglycan synthesis; wound healing and tissue remodeling; broad gene-expression modulation.
- BPC-157: accelerated healing of tendon, ligament, muscle, and bone injuries in animal models; angiogenesis and anti-inflammatory effects.
- TB-500: cell migration, angiogenesis, and tissue remodeling via actin regulation in animal models.
- Proposed complementarity across matrix remodeling, cytoprotective signaling, and cell motility, which is the rationale for the combination.
- No human adverse-effect data exist for the blend; the following are component-level observations.
- Injection-site reactions, including redness, are the most commonly reported effect.
- Mild drowsiness has been reported in community use, attributed to the GHK-Cu component.
- Copper-related effects with repeated dosing, including theoretical accumulation.
- A practical hazard specific to blends: the fixed ratio makes it impossible to identify or isolate which component caused an adverse effect.
Warnings and contraindications
Important safety information. This is not exhaustive — read the full prescribing information and consult your prescriber or pharmacist.
- No FDA-approved labeling exists; the following reflect the blend's status and the limits of its evidence, not established label warnings.
- This is a blend, not a studied compound. No published clinical trial has evaluated this combination as a blend; whatever evidence exists belongs to the individual components studied separately, and combining them does not carry that evidence forward.
- The ratio is fixed by the seller, not derived from clinical data. Because all components share one vial, a single draw delivers all of them together and none can be titrated, paused, or dose-adjusted independently. If one component causes a problem, the only options are stopping everything or continuing everything.
- Pre-blending does not change the regulatory status of the individual components; each substance retains its own status, and the blend as a product is not on any FDA list.
- Co-lyophilized multi-peptide stability is not established. Compatibility, pH interactions, and per-component degradation rates in a shared vial are generally not characterized by the vendors selling these blends.
- A stability caveat specific to copper-containing blends: GHK-Cu is a copper(II) complex, and pre-mixing it with BPC-157 raises documented pH-compatibility concerns. Copper(II) is also a redox-active metal capable of catalyzing oxidative degradation of other peptides in solution. Per-component degradation rates in a shared copper-containing vial are not characterized by the vendors selling these blends. Sourcing the components as separate vials avoids this entirely and preserves independent dosing.
- The 5:1:1 mass ratio reflects the components' different effective dose ranges (GHK-Cu in milligrams, BPC-157 and TB-500 in micrograms), not a clinically derived optimum. A single draw sized for one component may over- or under-deliver the others.
- Component status is unresolved and differs per substance: BPC-157 and TB-500 were removed from Category 2 in April 2026 but not added to the 503A bulks list (with the FDA proposing that TB-500 not be added), and injectable GHK-Cu is scheduled for a separate, later advisory committee meeting due before the end of February 2027.
- TB-500 is prohibited at all times in sport under WADA Section S0; BPC-157 has also appeared on the WADA list. This blend is not usable by tested athletes.
- Copper accumulation is a real consideration with repeated GHK-Cu dosing, and is the main reason community protocols cycle off; caution applies in copper-metabolism disorders such as Wilson disease.
- None of the three components has completed a human efficacy trial for these uses; safety in pregnancy and breastfeeding has not been studied.
- Not established; no FDA-approved labeling. Precautionary considerations carry over from the components: active or suspected malignancy (given proposed angiogenic and cell-migration effects), disorders of copper metabolism such as Wilson disease, known hypersensitivity to copper or to any component peptide, and use by athletes subject to anti-doping rules.
Reconstitution Steps
How to prepare the lyophilized vial. Confirm specifics with your pharmacist or prescriber.
- This is a multi-component blend supplied as a single co-lyophilized vial, so all components share one diluent volume and are drawn together in a fixed ratio. Confirm the total vial mass AND the per-component split before starting; the ratio cannot be adjusted after reconstitution.
- For this blend specifically: the standard vial is 70 mg total, split 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500 (a 5:1:1 ratio). Smaller vials use the same ratio. Confirm your vial's split before calculating.
- Expect a blue or blue-green tint after reconstitution from the copper component; that is normal for GHK-Cu and is not by itself a sign of a problem, though a color change over time may indicate degradation.
- Wash your hands and gather supplies: the blend vial, the diluent (typically bacteriostatic water), an alcohol swab, and a sterile syringe.
- Let the vial and diluent reach room temperature if they were refrigerated or frozen.
- Wipe the rubber stopper of both the blend vial and the diluent vial with a fresh alcohol swab and let them air dry.
- Draw the intended diluent volume into the syringe.
- Insert the needle into the vial and slowly release the diluent down the inside wall rather than directly onto the powder, to avoid foaming.
- Do not shake. Gently swirl or roll the vial until fully dissolved.
- Inspect the solution: it should be clear with no visible particles. Do not use if cloudy or containing particles.
- Calculate concentration per component, not just for the blend: divide EACH component's mass by the same diluent volume. The calculator on this page computes a single concentration, so run it once per component using that component's mass.
- Label the vial with the reconstitution date and the full per-component concentration breakdown, and store as directed under reconstituted storage.
US regulatory status
Classifications are public record but can change. For reference only, not legal advice.
Development: GLOW has no development history of its own: it is a vendor and community construct, and no published study has evaluated the three-peptide combination together in humans or animals. Its component histories are separate and unequal. GHK-Cu is the most-studied of the three, with a large research base (mostly in vitro and animal, plus small human topical studies) in wound healing and skin regeneration dating to Loren Pickart's isolation of GHK from human plasma in the 1970s; its topical use is a lawful cosmetic application, while injectable use is a compounded, unapproved one. BPC-157 has an extensive preclinical literature with human evidence limited to a few small uncontrolled pilots. TB-500 has animal wound-healing data but no completed published human efficacy trial. The regulatory paths have now diverged: BPC-157 and TB-500 went to the July 23, 2026 Pharmacy Compounding Advisory Committee meeting, while injectable GHK-Cu was scheduled for a separate later meeting due before the end of February 2027, alongside Melanotan II, LL-37, Dihexa acetate, and PEG-MGF.
Notes: GLOW is not FDA-approved, and blends as such are not on any FDA list; compounding eligibility is determined per substance, and pre-blending does not change any component's status. The three components are on different tracks: BPC-157 and TB-500 were removed from FDA Category 2 on April 15, 2026 but not added to the 503A bulks list, and went before the Pharmacy Compounding Advisory Committee on July 23, 2026 (with the FDA proposing that TB-500 not be added); injectable GHK-Cu was also removed from Category 2 but is scheduled for a later advisory committee meeting due before the end of February 2027. Topical GHK-Cu is separately lawful as a cosmetic ingredient, which does not extend to injectable use. Because eligibility is per substance, this blend has a lawful compounding path only if every component does. Verify each against the current FDA list. TB-500 is prohibited in sport under WADA Section S0. None of the components is a controlled substance. (Status current as of mid-2026.)
International status
Pharmacokinetics
Storage and handling
Important Notes
Practical considerations for consistency and safety.
- No published trial has evaluated GHK-Cu, BPC-157, and TB-500 together; the synergy claim is a vendor hypothesis, not a finding.
- Pre-mixing GHK-Cu with BPC-157 raises real pH-stability concerns, and copper(II) is redox-active and can catalyze oxidative degradation of other peptides. Unlike the Wolverine blend, this is a genuine chemistry objection to the single-vial format; separate vials avoid it.
- The 5:1:1 ratio exists because GHK-Cu is dosed in milligrams while BPC-157 and TB-500 are dosed in micrograms, not because GHK-Cu is five times more important.
- The components are on different regulatory tracks: BPC-157 and TB-500 went before the FDA advisory committee on July 23, 2026, while injectable GHK-Cu goes to a later meeting due before the end of February 2027.
- Copper accumulation is the main reason community protocols cycle off; topical GHK-Cu is lawful as a cosmetic, injectable is not.
Lifestyle Factors
- Community protocols typically cycle (commonly weeks on, weeks off), with copper accumulation from the GHK-Cu component cited as the main driver of the off period.
- Human lifestyle interactions are not characterized for any component in this context.
References
Related compounds
Important disclaimer
This page is an educational reference, not medical advice, a diagnosis, or a treatment recommendation, and not a substitute for your prescriber or pharmacist. Approval and regulatory status varies by compound and can change. Always confirm against current prescribing information and consult a qualified healthcare professional before making any decision about a medication.